接受新辅助化疗的卵巢癌患者静脉血栓栓塞事件的发生率与发生时机
本研究为单学术机构回顾性队列研究,纳入2009年1月至2014年5月接受新辅助化疗的卵巢、输卵管或原发腹膜癌患者125例,其中13例(10.4%,95%CI 6.1-17.2%)以静脉血栓栓塞为首发症状而被排除,剩余112例中30例(26.8%,95%CI 19.3-35.9%)发生静脉血栓栓塞。作者认为需关注化疗期间(新辅助和辅助)的血栓预防。
要点
- 125例中13例(10.4%)以静脉血栓栓塞为首发症状,被排除后续分析。
- 112例可评估患者中30例(26.8%)发生静脉血栓栓塞。
- 新辅助化疗期间13例(11.6%)、术后6例(5.4%)、辅助化疗期间11例(9.9%)发生血栓。
核心结论
- 在接受新辅助化疗的卵巢癌患者中,约四分之一发生新诊断的静脉血栓栓塞,其中近半数在间歇性减瘤术前化疗周期中被诊断。
- 作者认为,为降低静脉血栓栓塞率,有必要额外关注该患者群体化疗期间(新辅助和辅助)的血栓预防。
研究设计与样本
- 单学术机构回顾性队列研究,纳入2009年1月至2014年5月诊断为卵巢、输卵管或原发腹膜癌并接受新辅助化疗的患者125例。
主要发现
- 125例中13例(10.4%,95%CI 6.1-17.2%)以静脉血栓栓塞为首发症状,被排除进一步分析。
- 112例可评估患者中30例(26.8%,95%CI 19.3-35.9%)发生静脉血栓栓塞。
- 按治疗阶段,新辅助化疗期间13例(11.6%,95%CI 6.8-19.1%)发生静脉血栓栓塞,术后6例(5.4%,95%CI 2.4-11.5%),辅助化疗期间11例(9.9%,95%CI 5.5-17%)。
- 4例透明细胞组织学患者中2例发生静脉血栓栓塞。
临床怎么用
- 作者认为,为降低静脉血栓栓塞率,有必要额外关注该患者群体化疗期间(新辅助和辅助)的血栓预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify the incidence and timing of venous thromboembolism as well as any associated risk factors in patients with ovarian, fallopian tube, or primary peritoneal cancer undergoing neoadjuvant chemotherapy. METHODS: We conducted a retrospective cohort study of patients diagnosed with ovarian, fallopian tube, and primary peritoneal cancer and receiving neoadjuvant chemotherapy from January 2009 to May 2014 at a single academic institution. The timing and number of venous thromboembolic events for the entire cohort were categorized as follows: presenting symptom, during neoadjuvant chemotherapy treatment, after debulking surgery, and during adjuvant chemotherapy. RESULTS: Of the 125 total patients with ovarian cancer undergoing neoadjuvant chemotherapy, 13 of 125 patients (10.4%, 95% confidence interval [CI] 6.1-17.2%) had a venous thromboembolism as a presenting symptom and were excluded from further analysis. Of the 112 total patients at risk, 30 (26.8%, 95% CI 19.3-35.9%) experienced a venous thromboembolism. Based on the phase of care, 13 (11.6%, 95% CI 6.8-19.1%) experienced a venous thromboembolism during neoadjuvant chemotherapy, six (5.4%, 95% CI 2.4-11.5%) developed a postoperative venous thromboembolism, and 11 (9.9%, 95% CI 5.5-17%) developed a venous thromboembolism during adjuvant chemotherapy. Two of the four patients with clear cell histology developed a venous thromboembolism in this cohort. CONCLUSION: Overall new diagnosis of venous thromboembolism was associated with one fourth of the patients undergoing neoadjuvant chemotherapy for ovarian cancer with nearly half of these diagnosed during chemotherapy cycles before interval debulking surgery. Efforts to reduce venous thromboembolism so far have largely focused on the postoperative period. Additional attention to venous thromboembolic prophylaxis during chemotherapy (neoadjuvant and adjuvant) in this patient population is warranted in an effort to decrease the rates of venous thromboembolism.
引用
- Greco PS, Bazzi AA, McLean K, et al. Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Obstet Gynecol. 2017. PMID: 28486358. doi:10.1097/AOG.0000000000001980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。